Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Velcade in advanced or relapsed MALT lymphoma
2005-003077-25Phase 2Completed
- Sponsor
- University Hospital Vienna
- Start
- Sep 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by University Hospital Vienna. Primary endpoint: Clinical response. Started Sep 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2005-003077-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003077-25.